Bioventus Inc.
A maker of orthobiologic therapies that help the body heal itself, Bioventus Inc. sells the EXOGEN ultrasound bone-healing system and Durolane joint injections for osteoarthritis, giving patients non-surgical options for orthopedic care. Founded in 2012 in Durham, North Carolina, the company was spun out of medical-technology firm Smith & Nephew. Its name blends the Greek word for life with the Latin for wind — fittingly, EXOGEN itself began as a separate company before joining the lineup.
Granted 32.3K
Granted 32.3K
Granted 39.8K
Granted 65.3K
Granted 40.5K
Granted 32.3K · Sold 10.0K
Granted 32.3K
Granted 127.3K
Granted 32.3K
Granted 32.3K
Granted 32.3K
Granted 32.3K · Sold 29.7K
Granted 15.6K
Granted 32.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Sutter Martin PDirector, 10% owner · 1 transaction | +0.2% | 13.14M | 32.3K | — | — |
| Bartholdson John A.Director, 10% owner · 1 transaction | +0.5% | 7.05M | 32.3K | — | — |
| Hawkins William ADirector · 1 transaction | +15.4% | 297.6K | 39.8K | — | — |
| Singleton Mark LeonardSVP & CFO · 8 transactions | +29.7% | 183.0K | 65.3K | — | — |
| D'Adamio AnthonySVP & General Counsel · 8 transactions | +20.2% | 158.0K | 40.5K | — | — |
| Nohra Guy PDirector · 2 transactions | +17.6% | 148.9K | 32.3K | — | 10.0K |
| Stalnecker Susan MDirector · 1 transaction | +30.5% | 138.2K | 32.3K | — | — |
| Claypoole Robert EPresident and CEO, Director · 4 transactions | +109.3% | 135.9K | 127.3K | — | — |
| Neels Guido JDirector · 1 transaction | +37.9% | 117.5K | 32.3K | — | — |
| Ladone Mary KayDirector · 1 transaction | +40.9% | 111.3K | 32.3K | — | — |
| Beyer PatDirector · 1 transaction | +42.2% | 108.7K | 32.3K | — | — |
| McMurry-Heath MichelleDirector · 3 transactions | +3.5% | 77.3K | 32.3K | — | 29.7K |
| Church Katrina JSVP & Chief Compliance Officer · 8 transactions | +15.5% | 64.2K | 15.6K | — | — |
| Cowdy Philip G.Director · 1 transaction | +275.9% | 44.0K | 32.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -39.7K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.